Abstract:Abstract Background CARs are simulated receptors containing an extracellular single-chain variable fragment (scFv), a transmembrane domain, as well as an intracellular region of immunoreceptor tyrosine-based activation motifs (ITAMs) in association with a co-stimulatory signal. Main body Chimeric antigen receptor (CAR) T cells are genetically engineered T cells to express a receptor for the recognition of the particular surface marker that has given rise to advances in the treatment of blood disorders. The CAR T cells obtain supra-physiological properties and conduct as “living drugs” presenting both immediate and steady effects after expression in T cells surface. But, their efficacy in solid tumor treatment has not yet been supported. The pivotal challenges in the field of solid tumor CAR T cell therapy can be summarized in three major parts: recognition, trafficking, and surviving in the tumor. On the other hand, the immunosuppressive tumor microenvironment (TME) interferes with T cell activity in terms of differentiation and exhaustion, and as a result of the combined use of CARs and checkpoint blockade, as well as the suppression of other inhibitor factors in the microenvironment, very promising results were obtained from the reduction of T cell exhaustion. Conclusion Nowadays, identifying and defeating the mechanisms associated with CAR T cell dysfunction is crucial to establish CAR T cells that can proliferate and lyse tumor cells severely. In this review, we discuss the CAR signaling and efficacy T in solid tumors and evaluate the most significant barriers in this process and describe the most novel therapeutic methods aiming to the acquirement of the promising therapeutic outcome in non-hematologic malignancies.

CAR T cells in solid tumors and metastasis: paving the way forward

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR T cell therapy: Current limitations and advancements in treating solid tumors

CAR T cells in solid tumors: challenges and opportunities

Hurdles to breakthrough in CAR T cell therapy of solid tumors

Prospects and challenges for use of CAR T cell therapies in solid tumors

CAR-T cells: the long and winding road to solid tumors

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

A long way to the battlefront: CAR T cell therapy against solid cancers.

CAR-T in solid tumors: Blazing a new trail through the brambles

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

CAR-T cell therapy: current limitations and potential strategies

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment

Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment